By David Wallace – September 23, 2026 Mimrylo (rusfertide) has been added as a Category 1 treatment option for both low- and high-risk polycythemia vera (PV) in the National Comprehensive Cancer Network’s updated guidelines. For patients who need frequent phlebotomies, the update is another reason to ask whether a medicine designed to control hematocrit could […]
FDA Approves Mimrylo (Rusfertide) for Polycythemia Vera
By David Wallace – September 1, 2026 The U.S. Food and Drug Administration approved Mimrylo™ (mim-rahy-loh), the brand name for rusfertide, on August 28, 2026, for the treatment of erythrocytosis in adults with polycythemia vera (PV). Erythrocytosis means the body is making too many red blood cells. Mimrylo is the first FDA-approved hepcidin mimetic for […]
Divesiran Cuts Phlebotomy Need in Phase 2 PV Trial
By David Wallace Silence Therapeutics reported that divesiran met the primary endpoint of the randomized Phase 2 SANRECO trial. Among 48 phlebotomy-dependent polycythemia vera patients, 88% of those receiving divesiran maintained hematocrit below 45% without phlebotomy during weeks 18 through 36, compared with 19% on placebo. The difference was statistically significant. What the Phase 2 […]
What Are The Key Factors in Predicting Polycythemia Vera Progression?
by David Wallace A new study has shed light on the factors that may predict polycythemia vera (PV) disease progression. The REVEAL study, presented at the 2024 European Hematology Association Congress, has identified five key characteristics that could help doctors better understand which patients are at higher risk of their condition worsening over time. Polycythemia […]
